Literature DB >> 1831625

Quantification of epidermal histological changes induced by topical retinoids and CD271 in the rhino mouse model using a standardized image analysis technique.

M Bouclier1, A Chatelus, J Ferracin, C Delain, B Shroot, C N Hensby.   

Abstract

The rhino mouse has been used as an experimental model to screen topically active comedolytic agents. Adult rhino mice were treated on the back once daily for 5 consecutive days per week during 3 weeks. Skin histological preparations were analyzed by image analysis techniques to quantify the number of epidermal comedones, comedo profile and epidermal thickness. Using both a negative (treated with acetone) and a positive (treated with Aberel gel 0.025%) control group of animals in all experiments conducted over a period of about 3 years, we defined the upper and lower limit of acceptability of the results. Topical treatment with an acetone solution of all-trans retinoic acid (0.01, 0.03, 0.1%) and 13-cis-retinoic acid (0.1%) induced comedolysis and a marked increase in epidermal thickness. Commercial preparations of all-trans retinoic acid (Aberel lotion, gel and cream, Retin A cream, Retacnyl cream) presented a similar comedolytic activity. However, the epidermal thickening was higher with Retin A and weaker with Retacnyl. CD271, a new modulator of cell differentiation, applied either in acetone solution (0.01, 0.1%) or in lotion, gel or cream formulations (0.1%) also demonstrated a marked activity (i.e. comedolysis and epidermal thickening). These data confirm that the rhino mouse model can be used to assay drugs applied either in solvent or in topical formulations. Activity in this model compares favorably with published clinical observations in the treatment of acne.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1831625     DOI: 10.1159/000210926

Source DB:  PubMed          Journal:  Skin Pharmacol        ISSN: 1011-0283


  6 in total

Review 1.  Retinoid pathway and cancer therapeutics.

Authors:  Nathan Bushue; Yu-Jui Yvonne Wan
Journal:  Adv Drug Deliv Rev       Date:  2010-08-03       Impact factor: 15.470

Review 2.  Adapalene. A review of its pharmacological properties and clinical potential in the management of mild to moderate acne.

Authors:  R N Brogden; K E Goa
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

3.  Preclinical assessment of dual CYP26[A1/B1] inhibitor, DX308, as an improved treatment for keratinization disorders.

Authors:  J G S Veit; Y Poumay; D Mendes; J Kreitinger; L Walker; A Paquet; C Menigot; F Zolezzi; A S Paller; P Diaz
Journal:  Skin Health Dis       Date:  2021-03-26

4.  Site-specific drug delivery to pilosebaceous structures using polymeric microspheres.

Authors:  A Rolland; N Wagner; A Chatelus; B Shroot; H Schaefer
Journal:  Pharm Res       Date:  1993-12       Impact factor: 4.200

5.  Low-dose Vitamin "A" Tablets-treatment of Acne Vulgaris.

Authors:  Merita Grajqevci Kotori
Journal:  Med Arch       Date:  2015-02-21

6.  Nuclear staining and relative distance for quantifying epidermal differentiation in biomarker expression profiling.

Authors:  Thora Pommerencke; Thorsten Steinberg; Hartmut Dickhaus; Pascal Tomakidi; Niels Grabe
Journal:  BMC Bioinformatics       Date:  2008-11-06       Impact factor: 3.169

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.